Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Post by gojotv!on Jul 20, 2021 1:19pm
221 Views
Post# 33575785

I wonder if ...

I wonder if ......we'd see a better result if the patients held in the formula a little longer.
Maybe it takes more time for cancer cells that have been treated with BCG to absorb the TLD-1433.
Another 15-20 minutes would be uncomfortable for the patients, but could be the tipping point that make all the difference.
And what about throat cancers? It would be easy to treat them using the same modality as bladder cancer... just gargle and go... providing TLD-1433 doesn't taste too bad...
Anyway, there's a long road of trials ahead, and right now, we're well ahead of competitors. The future is looking bright!

<< Previous
Bullboard Posts
Next >>